Liver Disease News and Research

RSS

The liver is one of the largest solid organs of the body. It is located in the upper right part of the abdomen. Most of the organ lies under cover of the rib cage.

Do cocoa flavanols influence heart and fatty liver risk factors?

A recent Nutrients review examined whether cocoa-rich dark chocolate influences cardiovascular and metabolic dysfunction-associated steatotic liver disease risk factors through antioxidant, anti-inflammatory, and endothelial effects. Evidence suggests modest improvements in biomarkers, but most data come from short-term studies, so definitive clinical benefits remain unproven.

16 Feb 2026

Study explores whether a bidirectional causal link exists between MASLD and sarcopenia

Metabolic dysfunction-associated steatotic liver disease (MASLD) and sarcopenia frequently coexist, yet their causal relationship and underlying mechanisms remain poorly defined.

13 Feb 2026

Aligning overnight fasting with sleep improves heart health

A new Northwestern Medicine study has personalized overnight fasting by aligning it with individuals' circadian sleep-wake rhythm - an important regulator of cardiovascular and metabolic function - without changing their caloric intake.

12 Feb 2026

Defective fat cells drive metabolic disease in lipodystrophy

Many people may have a dim view of their fat tissue, yet scientists have come to recognize adipose as a necessary and metabolically active organ, carrying out many vital functions within the body.

9 Feb 2026

Large trials show statins rarely cause reported side effects

Cardiovascular disease results in around 20 million deaths worldwide and causes around a quarter of all deaths in the UK.

5 Feb 2026

Liver-derived protein supports bone health in males

New research suggests the liver plays a previously unrecognized role in bone health, but only in males.

5 Feb 2026

Engineered liver tissue model mimics early metabolic liver disease

More than 100 million people in the United States suffer from metabolic dysfunction-associated steatotic liver disease (MASLD), characterized by a buildup of fat in the liver.

3 Feb 2026

Unraveling liver injury mechanisms in familial hypobetalipoproteinemia

Familial Hypobetalipoproteinemia (FHBL), caused by variants in the apolipoprotein B (APOB) gene, is a rare autosomal co-dominant monogenic disorder characterized by lifelong low plasma levels of total cholesterol, low-density lipoprotein cholesterol (LDL-C), and APOB.

24 Jan 2026

Cigarette compound exposure drives sorafenib resistance in hepatocellular carcinoma

A research team led by Professor Yuan Li at Nanjing Medical University published a research paper entitled "A Cigarette Compound-Induced Tumor Microenvironment Promotes Sorafenib Resistance in Hepatocellular Carcinoma via the 14-3-3η-Modified Tumor-Associated Proteome" in the Chinese Medical Journal.

23 Jan 2026

New study identifies the optimal exercise dose for reducing hepatic steatosis

Hepatic steatosis is a core pathological feature of metabolic dysfunction-associated steatotic liver disease (MASLD). It not only drives disease progression to intrahepatic conditions such as cirrhosis but also elevates the incidence and mortality risk of cardiovascular diseases and extrahepatic malignancies.

23 Jan 2026

Alterations in liver metabolism experienced by individuals with Down syndrome

Researchers at the University of Colorado Anschutz Linda Crnic Institute for Down Syndrome (Crnic Institute) have uncovered compelling evidence that individuals with Down syndrome experience significant alterations in liver metabolism, including elevated levels of bile acids in the bloodstream and other biomarkers of liver dysfunction.

22 Jan 2026

Expert guidance on fecal microbiota transplantation in liver disease

The gut microbiota plays a crucial role in maintaining host health and liver function. Fecal microbiota transplantation (FMT), an emerging therapeutic modality, has demonstrated promising potential in the treatment of chronic liver diseases.

22 Jan 2026

Myosteatosis: An emerging predictor of outcomes in chronic liver disease

Myosteatosis, the pathological infiltration of fat into skeletal muscle, is increasingly recognized as a key predictor of poor clinical outcomes across a spectrum of liver diseases.

22 Jan 2026

NuSHs can be a promising therapeutic strategy for preventing MASH-related hepatocellular carcinoma

Metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH), represent the most common chronic liver diseases in Western populations, driven largely by obesity and insulin resistance.

21 Jan 2026

Researchers discover how Mycoplasma pneumoniae acquires cholesterol from human hosts

A multidisciplinary team has uncovered a key mechanism that allows the human bacterium Mycoplasma pneumoniae-responsible for atypical pneumonia and other respiratory infections-to obtain cholesterol and other essential lipids directly from the human body.

16 Jan 2026

New oral drug safely lowers triglycerides and other blood lipids in Phase 1 trial

In a Phase 1 clinical study, researchers led by EPFL and their partners report that a new liver- and gut-targeted oral drug can safely lower triglycerides and other blood lipids.

16 Jan 2026

UC San Diego project aims to bioprint patient-specific transplantable human livers

Liver failure is one of the most serious and deadly medical conditions, claiming thousands of lives each year as patients in the United States wait for a donor organ.

14 Jan 2026

Gut bacteria compound during pregnancy protects offspring from fatty liver disease

Children born to mothers who consume a high-fat, high-sugar diet during pregnancy and breastfeeding face a higher risk of developing fatty liver disease later in life.

14 Jan 2026

PFAS exposure linked to gestational diabetes and insulin problems

Exposure to per- and polyfluoroalkyl substances (PFAS), a class of highly persistent environmental chemicals commonly referred to as "forever chemicals," is associated with a higher risk of gestational diabetes mellitus and altered markers of insulin resistance and insulin secretion, according to a new systematic review and meta-analysis led by researchers at the Icahn School of Medicine at Mount Sinai.

14 Jan 2026

Preclinical study reveals potential new treatment for severe liver fibrosis

Researchers at McMaster University are leading preclinical studies into a novel drug candidate developed by Espervita Therapeutics that has the potential to prevent and reverse liver fibrosis - a dangerous, disease-induced build-up of scar tissue in the liver that often leads to cancer.

13 Jan 2026